Medication info
Procincapsule 75mg (Pregabalin)

Procincapsule 75mg (Pregabalin)

Prescription medicationHard capsuleOral
Ingredient · strength
Pregabalin›75mg / 1 capsule
Manufacturer / importer
Korea Chorus Co., Ltd.
Appearance
A hard capsule with a brown upper part containing white powder and a white lower part.
Packaging
30 capsules/bottle, 60 capsules/bottle
Approval status
Active

MFDS item code 201707563 · Approved 2017.10.23 · Insurance code 647204610

Summary

Main use
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures
Who takes it
Adults · Children
Adult dose
The total daily dose of this medicine, as pregabalin, is administered orally in 2 divided doses, with or without food. Since this medicine is mainly excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be given at an initial dose of 150 mg daily. Based on each patient's response and tolerability, the dose may be increased to 300 mg daily after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg daily. 2) Central neuropathic pain Adults: This medicine may be given at an initial dose of 150 mg daily. Based on each patient's response and tolerability, the dose may be increased to 300 mg daily after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’) 2. Epilepsy Adults: This medicine may be given at an initial dose of 150 mg daily. Based on each patient's response and tolerability, the dose may be increased to 300 mg daily after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg daily. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg-450 mg daily. The initial dose is 75 mg twice daily (150 mg daily), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg daily). For patients who do not experience sufficient benefit at a dose of 300 mg daily, the dose may be increased within 1 week to 225 mg twice daily (450 mg daily). Clinical studies have also been conducted at a dose of 600 mg daily, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg daily are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with renal impairment Dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosing based on renal function ≥60: Initial dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID ≥30-<60: Initial dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID ≥15-<30: Initial dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID <15: Initial dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: Initial dose 25, maximum dose 100, single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = administered once daily a: The total daily dose (mg/day) should be divided as specified in the dosing regimen. b: The supplemental dose refers to an additional single dose. 6. Patients with hepatic impairment Dose adjustment is not necessary in patients with hepatic impairment. 8. Elderly patients (aged 65 years or older) Dose reduction may be necessary in elderly patients with impaired renal function.
Child dose
Children under 12 years of age: Use is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12-17 years: Use is not recommended because there are insufficient safety and efficacy data.

Ingredients

Manufacturer
Korea Chorus Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia.
View approved original text

This medication is used to alleviate peripheral and central neuropathic pain in adults. Additionally, it serves as an adjunct in managing seizure symptoms in patients with epilepsy. It is also effective in reducing muscle pain and discomfort due to fibromyalgia. This drug is used to improve pain and symptoms associated with various neurological disorders.

How to take

Adult dose

The total daily dose of this medicine, as pregabalin, is administered orally in 2 divided doses, with or without food. Since this medicine is mainly excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be given at an initial dose of 150 mg daily. Based on each patient's response and tolerability, the dose may be increased to 300 mg daily after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg daily. 2) Central neuropathic pain Adults: This medicine may be given at an initial dose of 150 mg daily. Based on each patient's response and tolerability, the dose may be increased to 300 mg daily after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’) 2. Epilepsy Adults: This medicine may be given at an initial dose of 150 mg daily. Based on each patient's response and tolerability, the dose may be increased to 300 mg daily after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg daily. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg-450 mg daily. The initial dose is 75 mg twice daily (150 mg daily), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg daily). For patients who do not experience sufficient benefit at a dose of 300 mg daily, the dose may be increased within 1 week to 225 mg twice daily (450 mg daily). Clinical studies have also been conducted at a dose of 600 mg daily, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg daily are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with renal impairment Dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosing based on renal function ≥60: Initial dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID ≥30-<60: Initial dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID ≥15-<30: Initial dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID <15: Initial dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: Initial dose 25, maximum dose 100, single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = administered once daily a: The total daily dose (mg/day) should be divided as specified in the dosing regimen. b: The supplemental dose refers to an additional single dose. 6. Patients with hepatic impairment Dose adjustment is not necessary in patients with hepatic impairment. 8. Elderly patients (aged 65 years or older) Dose reduction may be necessary in elderly patients with impaired renal function.

Child dose

Children under 12 years of age: Use is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12-17 years: Use is not recommended because there are insufficient safety and efficacy data.

Precautions

This medication affects the central nervous system and may increase the risk of suicidal thoughts or behavior, so careful observation of changes in mental state is necessary during treatment. Patients who are hypersensitive to the ingredients in this medication or have certain genetic metabolic disorders should not use it. Diabetic patients may need to adjust their blood sugar control medications due to weight gain after taking this drug. If allergic reactions such as angioedema occur, the medication should be stopped immediately, and elderly patients must be cautious of the risk of falls due to dizziness and drowsiness. This medication may cause visual disturbances such as blurred vision; if symptoms occur, consultation with a healthcare provider is necessary. Discontinuation of the medication may lead to withdrawal symptoms such as insomnia, headache, nausea, and anxiety, so the dosage should be gradually reduced according to a doctor's instructions. Patients with a history of drug abuse may be at a higher risk of dependence on this medication, so caution is required. Patients with impaired renal function should have their dosage adjusted, and it should be administered cautiously in patients with heart failure. Caution is needed when taken with other medications that have central nervous system depressant effects due to the risk of respiratory depression. In the early stages of pregnancy, there is a risk of fetal malformations, so women who are pregnant or planning to become pregnant should consult a physician and use effective contraceptive methods. Breastfeeding women should carefully decide on the use of this medication as it may be transmitted through breast milk, affecting the infant. When performing activities requiring attention, such as driving or operating machinery, there is a higher risk of accidents due to dizziness or drowsiness caused by this medication, so caution is necessary. In case of overdose, symptoms such as confusion, drowsiness, and depression may occur, and treatments such as hemodialysis may be required if necessary. This medication should be kept out of reach of children, and transferring it to another container may not be good for quality maintenance.

Side effects

Suicidal thoughts, suicidal behavior, depression, abnormal changes in mood and behavior, angioedema, facial swelling, swelling around the mouth, upper airway swelling, dizziness, drowsiness, loss of consciousness, confusion, mental disorders, blurred vision, vision changes, insomnia, headache, nausea, anxiety, diarrhea, influenza-like illness, restlessness, suicidal thoughts, pain, seizures, hyperhidrosis, misuse, abuse, dependence, congestive heart failure, severe respiratory depression, impaired respiratory function, respiratory disease, neurological disorders, kidney disorders, rhinitis, neutropenia, increased appetite, decreased appetite, hypoglycemia, confusion, disorientation, irritability, elation, decreased libido, depersonalization, sexual dysfunction, restlessness, mood disturbance, emotional blunting, mood elevation, hallucinations, abnormal dreams, increased libido, panic attacks, inability to inhibit, apathy, ataxia, abnormal motor coordination, balance disorders, amnesia, attention deficit, memory impairment, tremors, speech disorders, sensory abnormalities, sensory loss, sedation, drowsiness disorder, cognitive impairment, nystagmus, language disorders, dyskinesia, reduced reflexes, motor abnormalities, psychomotor agitation, positional dizziness, hyperesthesia, burning sensation, action tremor, syncope, confusion, hypokinesia, olfactory abnormalities, loss of taste, writing difficulties, diplopia, loss of indirect vision, visual field disturbances, visual field deficits, photophobia, dry eyes, eye swelling, decreased vision, eye pain, eye fatigue, excessive tearing, eye irritation, mydriasis, during vibration, changes in depth perception of the visual field, strabismus, brightness of the visual field, dizziness, auditory hyperesthesia, first-degree AV block, tachycardia, sinus bradycardia, sinus tachycardia, sinus arrhythmia, hypotension, hypertension, flushing, facial flushing, peripheral coldness, dyspnea, epistaxis, cough, nasal congestion, rhinitis, snoring, throat tension, nasal dryness, respiratory depression, vomiting, abdominal distension, constipation, dry mouth, meteorism, excessive salivation, gastroesophageal reflux, oral sensory loss, ascites, dysphagia, pancreatitis, sweating, papular rash, urticaria, cold sweats, muscle cramps, arthralgia, back pain, limb pain, cervical spasms, joint swelling, myalgia, muscle spasms, neck pain, muscle stiffness, rhabdomyolysis, urinary disorders, incontinence, decreased urination, renal failure, erectile dysfunction, delayed ejaculation, sexual dysfunction, dysmenorrhea, amenorrhea, mastalgia, breast discharge, breast enlargement, peripheral edema, edema, gait abnormalities, falls, feeling of intoxication, altered sensation, fatigue, chest tightness, generalized edema, pain, fever, chills, weakness, thirst, weight gain, increased alanine aminotransferase, increased serum creatine phosphokinase, increased aspartate aminotransferase, increased blood glucose, decreased platelet count, decreased serum potassium, weight loss, increased serum creatinine, decreased white blood cell count, hypersensitivity, allergic reactions, headache, keratitis, pulmonary edema, tongue swelling, itching, Stevens-Johnson syndrome, toxic epidermal necrolysis, urinary retention, gynecomastia, malaise, shock, anaphylactic-like reactions, skin-mucosal syndrome, erythema multiforme, delirium, paralysis, facial paralysis, affective disorder, drowsiness, confusion, depression, agitation, restlessness, exacerbation of seizures, gastrointestinal disorders, tinnitus, sleep disorders, skin diseases, increased BUN, hematochezia, ataxia, speech disorders, sensory abnormalities, memory impairment, attention deficit

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent air or moisture from entering. The recommended storage temperature is to maintain room temperature between 15 and 30 degrees Celsius.

Appearance and packaging

Appearance

A hard capsule with a brown upper part containing white powder and a white lower part.

Package unit

30 capsules/bottle, 60 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.